Clinical trials: Cardiovascular Condition
Hypertension
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients.
- Trial name
- NCT00615108
- Where
- 17 sites in Taiwan
- Volunteers
- 3,148 people
- Sponsor
- Boehringer Ingelheim
Stroke
ArmeoSenso - Reward
This study investigates the use of motivating/rewarding features in a computer based arm rehabilitation program. Half of the subjects will take part, besides receiving standard therapy, in a computer based program delivering a…
- Trial name
- NCT02257125
- Testing
- high incentive, low incentive
- Where
- 3 sites in Switzerland
- Volunteers
- 38 people
- Sponsor
- Cereneo AG
Stroke
COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke
Primary objective: Comparison of efficacy of the combination therapy (clopidogrel plus aspirin) and the aspirin alone (main comparison) to prevent any recurrent ischemic lesion .
- Trial name
- COMPRESS (NCT00814268)
- Testing
- Clopidogrel, Aspirin
- Where
- South Korea
- Volunteers
- 358 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients
The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard…
- Trial name
- NCT00852397
- Testing
- Apixaban
- Where
- 18 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Pfizer
Venous Thromboembolism
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-VEMED (NCT00714597)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 421 people
- Sponsor
- Sanofi
Tricuspid Regurgitation
Laplace Early Feasibility Study - Canada
The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
- Trial name
- NCT07171060
- Testing
- Laplace TTVR System
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Laplace Interventional, Inc
Stroke
Evaluation of the Benefit of the H'Ability Home Device Used in Supervised Self-rehabilitation at Home on the Autonomy of Post-stroke Patients
The goal of this clinical investigation is to evaluate the benefit of the H'Ability Home device used in supervised self-rehabilitation at home on the autonomy of post-stroke patients.
- Trial name
- NCT07202520
- Testing
- IVR : H'Ability Home, Control: paper-based exercise guide
- Where
- 5 sites in France
- Volunteers
- 44 people
- Sponsor
- H'ability
Hypotension, Orthostatic
Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
The purpose of this clinical study is to evaluate the clinical effect of midodrine hydrochloride (ProAmatine®) compared to placebo in patients with orthostatic hypotension by measuring the time to onset of near syncopal symptoms…
- Trial name
- NCT00555880
- Testing
- Midodrine hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Heart Failure, Congestive
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
GSK2798745 is being developed as a novel therapeutic intervention for the treatment of pulmonary edema associated with heart failure (HF) and is currently under investigation in the form of a compounded capsule.
- Trial name
- NCT02925546
- Testing
- GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
- Trial name
- ACCOMPLISH (NCT00170950)
- Testing
- Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 11,506 people
- Sponsor
- Novartis
Abdominal Aortic Aneurysm
Nectero EAST System Clinical Study
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment.
- Trial name
- stAAAble (NCT06001918)
- Testing
- Nectero EAST System
- Where
- 42 sites in United States, Australia and 1 more
- Volunteers
- 400 people
- Sponsor
- Nectero Medical, Inc.
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Coronary Artery Disease
Safety and Efficacy of Spinous Balloon Dilatation Catheter in CAD Treatment
The purpose of this study is to evaluate the safety and effectiveness of spinous process balloon dilation catheter (Plastic-Blade) in coronary vascular diseases, which is not inferior to the similar product on the market …
- Trial name
- NCT05342961
- Testing
- spinous balloon dilatation catheter (Plastic-Blade), spinous balloon dilatation catheter(lacrosse NSE)
- Volunteers
- 160 people
- Sponsor
- CCRF Inc., Beijing, China
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Multiple Myeloma
Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Objective of this study is to characterize the steady-state pharmacokinetics (PK) of thalidomide when given orally as monotherapy to subjects with multiple myeloma.
- Trial name
- NCT01937442
- Testing
- Thalidomide Celgene™
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Celgene
Ischemic Heart Disease, Stable Angina
BioFreedom US IDE Feasibility Trial
The purpose of this study is to collect additional safety and effectiveness data for on the Biosensors BioFreedom™ BA9 Drug Coated Coronary Stent in patients with native, de novo coronary artery disease.
- Conditions
- Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
- Trial name
- NCT02131142
- Testing
- BioFreedom drug coated coronary stent
- Where
- 13 sites in United States
- Volunteers
- 72 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease, Coronary Artery Stenosis
Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III)
BIOSOLVE-III Study is a pre-market, prospective, multi-center trial to assess the acute clinical performance of the DREAMS 2G Drug-Eluting Coronary Scaffold in de novo coronary artery lesions.
- Trial name
- BIOSOLVE-III (NCT02716220)
- Testing
- Percutaneous Coronary Intervention
- Where
- 8 sites in Belgium, Germany and 2 more
- Volunteers
- 61 people
- Sponsor
- Biotronik AG
Hypervascular Tumor and Arteriovenous Malformation
A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
To evaluate the efficacy and safety of transcatheter arterial embolization with E7040 in Japanese subjects with hypervascular tumor or arteriovenous malformation
- Trial name
- NCT01677624
- Testing
- E7040
- Where
- 10 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eisai Co., Ltd.
Type 2 Diabetes
An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients
An Observational Study to assess the Prevalence of Heart Failure in Type 2 Diabetes Patients in India.
- Trial name
- HF-Registry (NCT04072523)
- Where
- 26 sites in India
- Volunteers
- 621 people
- Sponsor
- AstraZeneca
Essential Hypertension
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic…
- Trial name
- NCT01237223
- Testing
- Aliskiren/Amlodipine 150/2.5 mg, Aliskiren/amlodipine 150/5 mg, Aliskiren 150 mg
- Where
- 11 sites in Japan
- Volunteers
- 1,342 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.